email article
The use of atorvastatin (Lipitor) did not reduce cartilage volume loss in patients with knee osteoarthritis (OA) over a period of 2 years, a placebo-controlled study found.
Among patients randomized to receive atorvastatin, 40 mg per day, the reduction of tibial cartilage volume was 1.66% per year, while for those given placebo, the reduction was 2.17%, for a between-group difference of 0.50% (95% CI -0.17 to 1.17,
P=0.14), reported Flavia M. Cicuttini, PhD, of Monash University in Melbourne, Australia, and colleagues. These findings do not support the use of atorvastatin as a disease-modifying agent in established knee OA, the researchers concluded in their study online in
Self-directed Digital Exercise Plan Improves Knee OA
medscape.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medscape.com Daily Mail and Mail on Sunday newspapers.
Sprifermin may confer greater benefit to patients at risk for rapid knee OA progression
healio.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from healio.com Daily Mail and Mail on Sunday newspapers.
Photo by Fly View Productions/Getty Images
Digitally treating osteoarthritis through clinical, evidence-based programs can be more effective at reducing pain and improving physical function than routine self-managed care, according to research from
Researchers from the University of Nottingham conducted a randomized control trial comparing traditional care with the digital intervention from Joint Academy to find differences in outcomes for knee osteoarthritis.
Joint Academy is an online treatment program that connects patients with a licensed physical therapist who guides them through daily personalized exercises and answers any user questions. The platform tracks progress from week to week so the program can be modified to fit the patient’s needs.
(2)
NEW YORK CITY (dpa-AFX) - Today s Daily Dose brings you news about Lexicon s regulatory update on Sotagliflozin in heart failure; FDA approval of Pfizer s XALKORI in a new indication; Bicycle s pipeline progress update and Organogenesis progress in knee osteoarthritis trial.
Read on.
1. Bicycle Rides High on Pipeline Progress Update
Shares of Bicycle Therapeutics plc (BCYC) touched a new high on Thursday on the back of its pipeline progress update.
The company s lead drug candidate BT1718 is progressing in the phase IIa portion of the Cancer Research UK sponsored phase I/IIa clinical trial in patients with advanced solid tumors. Enrollment in two solid tumor cohorts, one in squamous non-small cell lung cancer (NSCLC) and the other in an all-comers basket cohort is ongoing at four clinical sites, with additional sites expected to begin enrolling patients during the first half of 2021.